Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

85th Annual Congress of the European Atherosclerosis Society

23-26 April 2017, Prague, Czech Republic

ODYSSEY APPRISE offers insights into the real world use of PCSK9 inhibitor

ODYSSEY APPRISE offers insights into the real world use of PCSK9 inhibitor

What do we know about patients receiving a PCSK9 inhibitor in real world practice? In the case of alirocumab, what will be the usual dose regimen? These and other questions were the driver for the ODYSSEY APPRISE study, the first European/Canadian study which focused on…

read more »
New EAS Consensus Panel Statement: LDL causes ASCVD

New EAS Consensus Panel Statement: LDL causes ASCVD

85rd Annual Congress of the European Atherosclerosis Society (EAS), April 23-26th, Prague, Czech Republic Yesterday the EAS Consensus Panel published a new Consensus Statement confirming that LDL causes ASCVD. While there has been extensive evidence implicating LDL as a major modifiable cardiovascular risk factor, others…

read more »